Tricida Inc

Tricida — Corporate Update (October 2020)

19 slides from Tricida's corporate update, Oct 29, 2020

  1. Slide 1: Treating Metabolic Acidosis and Slowing the Progression of Chronic Kidney Disease

    Exhibit 99.1 Treating Metabolic Acidosis and Slowing the Progression of Chronic Kidney Disease Investor Presentation – End-of-Review Type A Meeting Update October 2020

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements Any statements contained in this presentation or made during the accompanying oral presentation that are not statements of historical facts are forward-looking statements as defined under the Federal securities laws. Examples of such statements include our plans, beliefs,

  3. Slide 3: Executive Summary

    Executive Summary • Tricida has worked with FDA on accelerated approval for veverimer since 2017 • Prior to the End-of-Review Type A meeting, Tricida had 20 relevant FDA interactions all of which focused on development of veverimer based solely on the use of serum bicarbonate as the surrogate endpoi

  4. Slide 4: Key FDA Interactions: No Prior Indication of a Requirement for CKD Progression Data

    20 Key FDA Interactions: No Prior Indication of a Requirement for CKD Progression Data for Accelerated Approval • Feb 2017: FDA agreement on Accelerated Approval • Aug 2019: Teleconference to discuss assessments of Program physical functioning in VALOR-CKD protocol • May 2017: FDA comments on TRCA-3

  5. Slide 5: Tricida Believes that Veverimer Is an Appropriate Candidate for Accelerated Approval

    Tricida Believes that Veverimer Is an Appropriate Candidate for Accelerated Approval • End-stage renal disease (ESRD) is a serious disease and data support the link between metabolic acidosis and progression of CKD • There is a high unmet need for an approved therapy • Serum bicarbonate is a surroga

  6. Slide 6: Deep Understanding of the Surrogate Effect and How It Reasonably Likely Translates to Clinical Benefit

    Tricida has a Deep Understanding of the Surrogate Effect and How It Reasonably Likely Translates to Clinical Benefit • Tricida focused the End-of-Review Type A meeting on the topic of whether the magnitude of treatment effect observed in TRCA-301/301E was reasonably likely to predict clinical benefi

  7. Slide 7: Relevant FDA Comments in the CRL and July Advice Letter

    Relevant FDA Comments in the CRL and July 30 Advice Letter • CRL indicated that FDA was seeking additional data from at least one additional adequate and well-controlled study demonstrating the efficacy of veverimer for the treatment of metabolic acidosis associated with CKD • In the CRL, the FDA ex

  8. Slide 8: Tricida Now Believes FDA Will Require Data on CKD Progression for Accelerated Approval

    Tricida Now Believes FDA Will Require Data on CKD Progression for Accelerated Approval of Veverimer • During the End-of-Review Type A meeting, Tricida presented information and made proposals that the company believes addressed the issues raised by the FDA in the CRL, including: – Information to sup

  9. Slide 9: Current Status

    Current Status • As of October 28, 2020, the VALOR-CKD trial has randomized 1,208 of 1,600 patients with an average treatment duration of ~11 months and has accrued 42 of the ~500 required primary endpoint events • Tricida is evaluating whether it is possible to provide the FDA with interim data on

  10. Slide 10: Metabolic Acidosis in CKD – An Unmet Need

    Metabolic Acidosis in CKD – An Unmet Need Managing Risk Clinical Practice The Goals of Treatment Factors of CKD Guidelines of Metabolic Acidosis are to: Progression KDIGO & KDOQI Good management to recommend treatment for 1 2 3 prevent nutritional decline, people with CKD whose functional decline, a

  11. Slide 11: Veverimer's Benefits Outweigh the Risks Associated with Use

    Tricida Believes Veverimer’s Benefits Outweigh the Risks Associated with Use Veverimer – Potential Benefits Veverimer – Potential Risks Benefit The safety of up to 1 year of treatment with veverimer has been Serum Bicarbonate: studied in a complex population of patients with Stage 3 − 4 CKD and  Ra

  12. Slide 12: Organizational Update and Financial Position

    Organizational Update and Financial Position • Tricida is re-organizing the company to extend its financial runway in order to maximize its options for bringing veverimer to patients – Significantly reducing its headcount – Tricida will discuss its commitments with vendors and contract service provi

  13. Slide 13: Thank You

    THANK YOU IRICIDA

  14. Slide 14: Supplemental Information

    Supplemental Information IRICIDA

  15. Slide 15: Two Independent Models Describe Association between Serum Bicarbonate and CKD Progression

    Two Independent Models Based on Observational Data Consistently Describe the Association between Serum Bicarbonate and CKD Progression Single Baseline Model Time-Dependent Model Data Source Sunnybrook Hospital, Canada OptumLabs Data Warehouse, U.S. Sample Size (N) 2,378 24,384 Population CKD G3 – 5

  16. Slide 16: Randomized Controlled Trials Show Clinical Benefit of Group Mean Treatment Effects of 2–3 mEq/L

    Randomized Controlled Trials Show Clinical Benefit of Group Mean Treatment Effects of 2 – 3 mEq/L • A meta-analysis of 14 randomized controlled trials (N=1,394) found that increasing serum bicarbonate resulted in slower decline of kidney function – Average increase in bicarbonate • 3.3 mEq/L (95% CI

  17. Slide 17: A Treatment Effect Is Reasonably Likely to Predict Clinical Benefit

    A Treatment Effect of ≥ 2 mEq/L is Reasonably Likely to Predict Clinical Benefit with a HR Consistent with Other Approved Cardio-Renal Drugs HR = Hazard Ratio. Tangri et al., NKF SCM, 2018. Data on file. Brenner et al., NEJM, 2001. Lewis et al., NEJM, 2001. Wallentin et al., NEJM, 2009. 17

  18. Slide 18: Treatment Effect in TRCA-301/301E Should be Described by Difference in Medians

    Magnitude of Treatment Effect Observed in TRCA-301/301E Should be Described by the Difference in Medians • Post-hoc analysis of change from baseline in serum bicarbonate from TRCA-301/301E showed that the data were not normally distributed – Shapiro-Wilk test (p < 0.05) at Week 12 and Week 52 • Thus

  19. Slide 19: Magnitude of Effect: Patients Receiving Veverimer Are Reasonably Likely to Derive Benefit

    Magnitude of Effect: Patients Receiving Veverimer Are Reasonably Likely to Derive Benefit Substantially more patients on veverimer than placebo have large increases in serum bicarbonate (e.g., >3, >4, >5 mEq/L) Distribution of mean changes from baseline in all bicarbonate values over the 52-week TRC

Tricida — Corporate Update (October 2020) on 6ix